Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 6Unknown 4Not yet recruiting 3Completed 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 7Breast 3Thoracic 1CNS 1

Conditions

Breast Neoplasms 2Female Breast Cancer Patients 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × fluzoparib × Breast × Clear all
NCT07353437 2026-01-20

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

Fudan University

Phase 2 Not yet recruiting
334 enrolled
Breast

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Fudan University

Phase 2 Not yet recruiting
260 enrolled
Breast

Breast Neoplasms

NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Female Breast Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡